产品名称 人唾液酸结合Ig样凝集素7(SIGLEC7) 货号 YXY-sw16284 价格说明 价格:商品在爱采购的展示标价,具体的成交价格可能因商品参加活动等情况发生变化,也可能随着购买数量不同或所选规格不同而发生变化,如用户与商家线下达成协议,以线下协议的结算价格为准,如用户在爱采购上完成线上购买,则最终以订单结算页...
百度爱采购为您找到401家最新的siglec-7轴产品的详细参数、实时报价、行情走势、优质商品批发/供应信息,您还可以免费查询、发布询价信息等。
AIMS: We examined serum levels of Siglec-7, a transmembrane receptor that regulates immune activity, as a biomarker for mortality in patients with cirrhosis and acute kidney injury. METHODS: Serum Siglec-7 was measured in hospitalized patients with cirrhosis and acute kidney injury, as well as ...
When siglec-7 was expressed on COS or Chinese hamster ovary cells, it was able to mediate high levels of sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates, suggesting that it may be involved in cell-cell interactions. Among human peripheral blood leukocytes, ...
852237-54-8 917237-08-2 918802-70-7 92097-99-9 92430-00-7 926209-22-5 92670-00-3 92855-70-4 90302-91-3 90302-91-3 90302-91-3 90302-91-3 863434-13-3 869564-46-5 869564-46-5 869564-46-5 93614-11-0 940602-69-7 943083-58-7 944552-90-3 94420-00-5 944901-42-2 945493-...
小鼠唾液酸结合性免疫球蛋白样凝集素G(sialic acid-binding immunoglobulin-like lectin-G ,Siglec-G)是一种B细胞受体,抑制钙信号传递和细胞增殖。 生物通报道:小鼠唾液酸结合性免疫球蛋白样凝集素G(sialic acid-binding immunoglobulin-like lectin-G ,Siglec-G)是一种B细胞受体,抑制钙信号传递和细胞增殖。
Rat IgG2b kappa Isotype Control (eB149/10H5), PE-Cyanine7, eBioscience™ 分类 Monoclonal 类型 Antibody 克隆号 eBio440c 偶联物 PE-Cyanine7 查看其它偶联染料 激发/发射光谱 569/780 nm 查看光谱 形式 Liquid 浓度 0.2 mg/mL 纯化类型 Affinity chromatography 保存...
Description: This 7-239 monoclonal antibody reacts with human CD169, also known as Siglec-1 and Sialoadhesin. This type I transmembrane protein is a member of the sialic acid binding Ig-like lectin (Siglec) family. Expressed on macrophages and dendritic cells in peripheral blood, lymph nodes,...
本公司生产销售凝集素 凝集素 试剂盒,提供凝集素专业参数,凝集素价格,市场行情,优质商品批发,供应厂家等信息.凝集素 凝集素 品牌优博森|产地江苏|价格1800.00元|规格96T/48T|贮藏2-8℃|有效成分含量99%|服务免费代测|名称人唾液酸结合Ig样凝集素8(SIGLEC8)ELISA试剂盒|英文
3月30日,博奥信生物(Biosion)宣布与Pyxis Oncology签订授权协议。根据协议,Pyxis Oncology将获得博奥信生物创新抗体BSI-060T除大中华区外的全球开发和商业化独家许可,博奥信生物将获得1000万美元的首付款,还将有资格收到总额高达2.225亿美元的里程碑付款,以...